Abstract
Summary
Europe genetic testing market is expected to reach USD 17,537,937.49 thousand by 2031 from USD 5,533,644.49 thousand in 2023 with growing at a CAGR of 15.8% during the forecast period of 2024 to 2031.
Market Segmentation
Europe Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), By Country (Germany, France, U.K. Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe) - Industry Trends and Forecast to 2031
Overview of Global Genetic Testing Market Dynamics
Driver
• Growing prevalence of genetic disorders
Restrain
• High cost of genetic testing
Opportunity
• Strategic initiatives by the key market player
Market Players
Some of the key market players for Europe genetic testing market are:
• Thermo Fisher Scientific Inc.
• Invitae Corporation
• Bio-Rad Laboratories, Inc.
• PerkinElmer Inc.
• Illumina, Inc.
• QIAGEN
• F. Hoffmann-La Roche Ltd.
• Fulgent Genetics
• Myriad Genetics, Inc.
• Abbott
• Eurofins Scientific
• Sorenson Genomics
• BIO-HELIX
• Biocartis
• Cepheid (A subsidiary of Danaher)
• PacBio
• ELITechGroup
• Genes2Me
• Eugene Labs
• Otogenetics
• Mapmygenome
• MedGenome
• BioReference
• Natera, Inc.
Table of Contents
1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW OF THE EUROPE GENETIC TESTING MARKET 32
1.4 LIMITATIONS 34
1.5 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 TYPE LIFELINE CURVE 44
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.8 DBMR MARKET POSITION GRID 46
2.9 MARKET APPLICATION COVERAGE GRID 47
2.10 VENDOR SHARE ANALYSIS 48
2.11 SECONDARY SOURCES 49
2.12 ASSUMPTIONS 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 52
4.1 PESTAL ANALYSIS 55
4.2 PORTERS 5 FORCES 56
4.3 EPIDEMIOLOGY 57
5 EUROPE GENETIC TESTING MARKET: REGULATIONS 58
6 MARKET OVERVIEW 60
6.1 DRIVERS 62
6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 62
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 62
6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 63
6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 63
6.2 RESTRAINTS 64
6.2.1 HIGH COST OF GENETIC TESTING 64
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 65
6.3 OPPORTUNITIES 65
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 65
6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 66
6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 66
6.4 CHALLENGES 67
6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 67
6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 68
7 EUROPE GENETIC TESTING MARKET, BY TYPE 69
7.1 OVERVIEW 70
7.2 DIAGNOSTIC TESTING 74
7.3 PRENATAL TESTING 74
7.3.1 NON-INVASIVE SCREENING 75
- 7.3.1.1 WHOLE GENOME SEQUENCING 76
- 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 76
- 7.3.1.3 OTHERS 76
7.3.2 BY CONDITION 77
- 7.3.2.1 TRISOMY 21 77
- 7.3.2.2 KLINEFELTER SYNDROME 77
- 7.3.2.3 JACOBS SYNDROME 77
- 7.3.2.4 CYSTIC FIBROSIS 77
- 7.3.2.5 TURNER SYNDROME 78
- 7.3.2.6 TRISOMY 18 78
- 7.3.2.7 HEMOPHILIA 78
- 7.3.2.8 TRISOMY 13 78
- 7.3.2.9 MICRODELETION SYNDROME 78
- 7.3.2.10 FETAL GENDER 78
- 7.3.2.11 OTHERS 78
7.3.3 BY SCREENING TYPE 79
- 7.3.3.1 CARRIER SEQUENCING 79
- 7.3.3.2 SEQUENTIAL SEQUENCING 79
7.3.4 MATERNAL SERUM QUAD SCREENING 79
7.4 NEW-BORN SCREENING 80
7.4.1 SICKLE CELL DISEASE 80
7.4.2 CONGENITAL HYPOTHYROIDISM 81
7.4.3 PHENYLKETONURINA (PKU) 81
7.4.4 GALACTOSEMIA 81
7.4.5 MAPLE SYRUP URINE DISEASE 81
7.4.6 OTHERS 81
7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 81
7.6 CARRIER TESTING 82
7.6.1 MOLECULAR SCREENING TEST 82
7.6.2 BIOCHEMICAL SCREENING TEST 83
- 7.6.2.1 EXPANDED CARRIER SCREENING 83
- 7.6.2.2 PREDESIGNED PANEL TESTING 84
- 7.6.2.3 CUSTOM-MADE PANEL TESTING 84
- 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 84
- 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 84
- 7.6.2.4.2 PULMONARY CONDITIONS 85
- 7.6.2.4.3 NEUROLOGICAL CONDITIONS 85
- 7.6.2.4.4 OTHER CONDITIONS 85
7.7 OTHER TYPES 85
8 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY 86
8.1 OVERVIEW 87
8.2 POLYMERASE CHAIN REACTION 90
8.2.1 REAL-TIME PCR (QPCR) 91
8.2.2 DIGITAL PCR (DPCR) 91
8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 91
8.2.4 HOT-START PCR 91
8.2.5 MULTIPLEX PCR 91
8.2.6 OTHER PCR 91
8.3 DNA SEQUENCING (NGS-BASED TESTING) 92
8.3.1 NEXT GENERATION SEQUENCING (NGS) 92
8.3.2 SANGER SEQUENCING (SINGLE GENE) 92
8.3.3 OTHER 93
8.4 WHOLE GENOME SEQUENCING 93
8.5 MICROARRAYS 93
8.5.1 DNA MICROARRAYS 94
8.5.2 PROTEIN MICROARRAYS 94
8.5.3 OTHER MICROARRAYS 94
8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 94
8.7 OTHERS 95
9 EUROPE GENETIC TESTING MARKET, BY DISEASES 96
9.1 OVERVIEW 97
9.2 CANCER 100
9.2.1 BREAST 101
9.2.2 COLON 101
9.2.3 LUNG 101
9.2.4 PROSTATE 101
9.2.5 OTHERS 101
9.3 SICKLE CELL ANEMIA 102
9.4 THALASSEMIA 102
9.5 RARE GENETIC DISORDER 103
9.5.1 TRISOMY 21 103
9.5.2 MONOSOMY X 103
9.5.3 TRISOMY 13 104
9.5.4 MICRODELETION SYNDROME 104
9.5.5 TRISOMY 18 104
9.5.6 OTHERS 104
9.6 FRAGILE X SYNDROME 104
9.7 DUCHENNE MUSCULAR DYSTROPHY 105
9.8 HUNTINGTON'S DISEASE 105
9.9 CYSTIC FIBROSIS 106
9.10 OTHERS 106
10 EUROPE GENETIC TESTING MARKET, BY END USER 107
10.1 OVERVIEW 108
10.2 HOSPITALS 111
10.3 CLINICS 112
10.4 DIAGNOSTIC CENTERS 112
10.5 PRIVATE CLINICS 113
10.6 LABORATORY SERVICE PROVIDERS 113
10.7 PRIVATE LABORATORIES 114
11 EUROPE GENETIC TESTING MARKET, BY REGION 115
11.1 EUROPE 117
11.1.1 GERMANY 126
11.1.2 FRANCE 137
11.1.3 U.K 148
11.1.4 RUSSIA 159
11.1.5 ITALY 170
11.1.6 SPAIN 180
11.1.7 TURKEY 191
11.1.8 NETHERLANDS 202
11.1.9 SWITZERLAND 213
11.1.10 BELGIUM 224
11.1.11 REST OF EUROPE 235
12 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE 236
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS 237
14 COMPANY PROFILES 238
14.1 ILLUMINA, INC 238
14.1.1 COMPANY SNAPSHOT 238
14.1.2 REVENUE ANALYSIS 238
14.1.3 COMPANY SHARE ANALYSIS 239
14.1.4 PRODUCT PORTFOLIO 239
14.1.5 RECENT DEVELOPMENT 240
14.2 CEPHEID 241
14.2.1 COMPANY SNAPSHOT 241
14.2.2 REVENUE ANALYSIS 241
14.2.3 COMPANY SHARE ANALYSIS 242
14.2.4 PRODUCT PORTFOLIO 242
14.2.5 RECENT DEVELOPMENT 242
14.3 FULGENT GENETICS 243
14.3.1 COMPANY SNAPSHOT 243
14.3.2 REVENUE ANALYSIS 243
14.3.3 COMPANY SHARE ANALYSIS 244
14.3.4 PRODUCT PORTFOLIO 244
14.3.5 RECENT DEVELOPMENT 245
14.4 PERKINELMER INC 246
14.4.1 COMPANY SNAPSHOT 246
14.4.2 REVENUE ANALYSIS 246
14.4.3 COMPANY SHARE ANALYSIS 247
14.4.4 PRODUCT PORTFOLIO 247
14.4.5 RECENT DEVELOPMENT 247
14.5 THERMO FISHER SCIENTIFIC INC 248
14.5.1 COMPANY SNAPSHOT 248
14.5.2 REVENUE ANALYSIS 248
14.5.3 COMPANY SHARE ANALYSIS 249
14.5.4 PRODUCT PORTFOLIO 249
14.5.5 RECENT DEVELOPMENT 250
- 14.5.5.1 COLLABORATION 250
14.6 BIOREFERENCE 251
14.6.1 COMPANY SNAPSHOT 251
14.6.2 REVENUE ANALYSIS 251
14.6.3 PRODUCT PORTFOLIO 252
14.6.4 RECENT DEVELOPMENT 252
14.7 ELITECHGROUP 253
14.7.1 COMPANY SNAPSHOT 253
14.7.2 PRODUCT PORTFOLIO 253
14.7.3 RECENT DEVELOPMENTS 254
14.8 EUROFINS SCIENTIFIC 255
14.8.1 COMPANY SNAPSHOT 255
14.8.2 REVENUE ANALYSIS 255
14.8.3 PRODUCT PORTFOLIO 256
14.8.4 RECENT DEVELOPMENT 256
14.9 INVITAE CORPORATION 257
14.9.1 COMPANY SNAPSHOT 257
14.9.2 REVENUE ANALYSIS 257
14.9.3 PRODUCT PORTFOLIO 258
14.9.4 RECENT DEVELOPMENTS 258
14.10 MYRIAD GENETICS 259
14.10.1 COMPANY SNAPSHOT 259
14.10.2 REVENUE ANALYSIS 259
14.10.3 PRODUCT PORTFOLIO 260
14.10.4 RECENT DEVELOPMENT 260
14.11 ABBOTT 261
14.11.1 COMPANY SNAPSHOT 261
14.11.2 REVENUE ANALYSIS 261
14.11.3 PRODUCT PORTFOLIO 262
14.11.4 RECENT DEVELOPMENT 262
14.12 BIOCARTIS 263
14.12.1 COMPANY SNAPSHOT 263
14.12.2 REVENUE ANALYSIS 263
14.12.3 PRODUCT PORTFOLIO 264
14.12.4 RECENT DEVELOPMENTS 264
- 14.12.4.1 PARTNERSHIP 264
14.13 BIO-HELIX 265
14.13.1 COMPANY SNAPSHOT 265
14.13.2 PRODUCT PORTFOLIO 265
14.13.3 RECENT DEVELOPMENT 265
14.14 BIO-RAD LABORATORIES, INC 266
14.14.1 COMPANY SNAPSHOT 266
14.14.2 REVENUE ANALYSIS 266
14.14.3 PRODUCT PORTFOLIO 267
14.14.4 RECENT DEVELOPMENTS 267
14.15 EUGENE LABS 268
14.15.1 COMPANY SNAPSHOT 268
14.15.2 PRODUCT PORTFOLIO 268
14.15.3 RECENT DEVELOPMENT 268
14.16 F. HOFFMANN-LA ROCHE LTD 269
14.16.1 COMPANY SNAPSHOT 269
14.16.2 REVENUE ANALYSIS (PARENT COMPANY) 269
14.16.3 PRODUCT PORTFOLIO 270
14.16.4 RECENT DEVELOPMENT 270
14.17 GENES2ME 271
14.17.1 COMPANY SNAPSHOT 271
14.17.2 PRODUCT PORTFOLIO 271
14.17.3 RECENT DEVELOPMENT 271
14.18 MAPMYGENOME 272
14.18.1 COMPANY SNAPSHOT 272
14.18.2 PRODUCT PORTFOLIO 272
14.18.3 RECENT DEVELOPMENT 273
14.19 MEDGENOME 274
14.19.1 COMPANY SNAPSHOT 274
14.19.2 PRODUCT PORTFOLIO 274
14.19.3 RECENT DEVELOPMENT 275
14.20 NATERA, INC 276
14.20.1 COMPANY SNAPSHOT 276
14.20.2 REVENUE ANALYSIS 276
14.20.3 PRODUCT PORTFOLIO 277
14.20.4 RECENT DEVELOPMENT 278
14.21 OTOGENETICS 279
14.21.1 COMPANY SNAPSHOT 279
14.21.2 PRODUCT PORTFOLIO 280
14.21.3 RECENT DEVELOPMENT 280
14.22 PACBIO 281
14.22.1 COMPANY SNAPSHOT 281
14.22.2 REVENUE ANALYSIS 281
14.22.3 PRODUCT PORTFOLIO 282
14.22.4 RECENT DEVELOPMENT 282
14.23 QIAGEN 283
14.23.1 COMPANY SNAPSHOT 283
14.23.2 REVENUE ANALYSIS 283
14.23.3 PRODUCT PORTFOLIO 284
14.23.4 RECENT DEVELOPMENT 284
14.24 SORENSON GENOMICS 285
14.24.1 COMPANY SNAPSHOT 285
14.24.2 PRODUCT PORTFOLIO 285
14.24.3 RECENT DEVELOPMENT 285
15 QUESTIONNAIRE 286
16 RELATED REPORTS 289